eligibility_summary
Inclusion: ≥16, ECOG 0–2, r/r LBCL, most recent therapy TGA‑approved anti‑CD19 CAR T, PMR/CMR on PET/CT and ctDNA MRD+ between Day +25–100 post infusion, adequate hematologic, cardiac, renal, hepatic function, CRS/MAS/ICANS resolved, contraception and consent. Exclusion: prior grade‑4 CRS/ICANS, CD20‑ disease, active infection, relapse ≤3 mo after CD3xCD20 bispecific, primary/active CNS, autoimmune/immunosuppression, cognitive risk, HBV/HCV/HIV+, life expectancy <5 y, live vaccine <4 wk, pregnant/lactating, hypersensitivity, other barriers.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II MRD-directed consolidation after anti-CD19 CAR T in large B‑cell lymphoma. Arms: (A) epcoritamab alone, (B) epcoritamab + lenalidomide + rituximab (Epcor‑R2). Epcoritamab: subcutaneous CD3×CD20 bispecific T‑cell–engaging antibody, redirects patient T cells (CD3) to CD20+ lymphoma cells to induce perforin/granzyme-mediated killing and cytokine release. Rituximab: anti‑CD20 IgG1 monoclonal antibody, depletes B cells via ADCC, CDC, and apoptosis. Lenalidomide: immunomodulatory drug (IMiD), binds cereblon to degrade Ikaros/Aiolos, enhancing T/NK cell function, reducing pro-tumor cytokines, and exerting anti‑angiogenic/antiproliferative effects. Targets/pathways: CD20 on malignant B cells, CD3 on T cells, Fc‑mediated cytotoxic pathways, cereblon E3 ligase complex, ctDNA-defined MRD. Goal: eradicate residual CD20+ disease and prevent relapse post CAR T.